Haemophilia and Protein C Deficiency
Bringing About Innovation in Haemophilia Treatment
The information contained in this page is intended for UK and Irish healthcare professionals only.
Baxter is committed to actively listening to and working with the haemophilia community to proactively shape the future of haemophilia by focusing on personalised innovations and solutions.
Baxter's range of haemophilia therapies allows clinicians to choose the appropriate therapy based on individual patient needs.
Specifically, Baxter is:
- Supporting advocacy through community participation, including through patient and clinician education and expanding patient access to therapy
- Advancing its portfolio through new therapies to address unmet clinical needs
- Supporting haemophilia through patient homecare
Continuing Education
Our commitment to care continues through grants that support the creation of educational programs and symposia for medical healthcare professionals. These avenues offer opportunities for clinicians to engage in informative exchanges, and peer to peer discussion of latest evidence and clinical practice.
Related websites and resources
The Irish Haemophilia Society was founded in 1968 by members of the medical profession, people with haemophilia, their families and friends who felt the need to provide support and advice for members and to improve the quality of life for people with haemophilia.
For more information see their website:http://www.haemophilia.ie
